{
  "content": "Diagnosis:\nLocally advanced esophageal adenocarcinoma T3N1M0\n\nHistology:\nModerately differentiated adenocarcinoma of lower esophagus\nHER2 negative\nPDL1 CPS 10\n\nPrevious treatment:\nCompleted neoadjuvant FLOT chemotherapy March-July 2024\nPartial response on interval imaging\n\nCurrent situation:\nPost-operative recovery following Ivor Lewis esophagectomy 15 August 2024\n\nTrial Registration:\nSuccessfully screened for the AEGIS trial (Phase III randomized controlled trial of adjuvant immunotherapy versus observation in patients with resected esophageal adenocarcinoma)\n\nBaseline assessments completed including:\nCT chest/abdomen/pelvis 1 September 2024 - no evidence of residual or metastatic disease\nECG - normal sinus rhythm\nBloods including thyroid function, cortisol, and autoimmune screen all within normal range\n\nTrial participation:\nRandomized to treatment arm\nFirst dose of trial medication (durvalumab) scheduled for 15 September 2024\nTrial-specific toxicity monitoring and QoL assessments completed\nProvided with trial emergency card and 24-hour contact numbers\n\nFollow up plan:\nWeekly review for first 4 weeks of trial treatment\nTrial-specific imaging at 12 weeks\nRegular MDT discussion as per protocol\n\nI have discussed the trial protocol in detail with [redacted name] including the requirement for regular blood tests and imaging. We have reviewed potential side effects of immunotherapy and provided written information about managing immune-related adverse events. [redacted name] demonstrates good understanding of the trial requirements and has provided written informed consent.",
  "output": {
    "primary_cancer": {
      "site": "esophagus, lower",
      "year": 2024,
      "metastases": "none",
      "tnm_stage": "T3N1M0",
      "histopathology_status": "moderately differentiated adenocarcinoma",
      "biomarker_status": "HER2 negative, PDL1 CPS 10",
      "cancer_timeline": [
        {
          "type": "treatment_systemic_start",
          "value": "Started neoadjuvant FLOT chemotherapy",
          "year": 2024,
          "month": 3
        },
        {
          "type": "treatment_systemic_change",
          "value": "Completed neoadjuvant FLOT chemotherapy with partial response",
          "year": 2024,
          "month": 7
        },
        {
          "type": "treatment_surgery",
          "value": "Ivor Lewis esophagectomy",
          "year": 2024,
          "month": 8
        },
        {
          "type": "anatomical_finding",
          "value": "CT chest/abdomen/pelvis shows no evidence of residual or metastatic disease",
          "year": 2024,
          "month": 9
        },
        {
          "type": "clinical_trial_update",
          "value": "Successfully screened and randomized to treatment arm of AEGIS trial",
          "year": 2024,
          "month": 9
        }
      ]
    },
    "patient_facts": [
      {
        "type": "investigation_finding",
        "value": "Normal ECG showing sinus rhythm"
      },
      {
        "type": "investigation_finding",
        "value": "Normal thyroid function, cortisol, and autoimmune screen"
      }
    ],
    "status_updates": [
      {
        "type": "clinical_summary",
        "value": "Locally advanced esophageal adenocarcinoma post neoadjuvant chemotherapy and surgery, now enrolled in adjuvant immunotherapy trial"
      },
      {
        "type": "update_to_treatment",
        "value": "Randomized to treatment arm of AEGIS trial, durvalumab to commence 15 September 2024"
      },
      {
        "type": "planned_investigation",
        "value": "Trial-specific imaging at 12 weeks"
      },
      {
        "type": "follow_up_referral",
        "value": "Weekly review for first 4 weeks of trial treatment"
      }
    ]
  }
}